We are monitoring the impact of COVID-19 on APAC Gene Therapy Market Get in touch with us for detailed analysis Know More
Pulished Date March, 2021
ID: 11386
Share on
Share on

APAC Gene Therapy Market Research Report - Segmented By Vector Type, Application and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Size, Share, Trends, COVID-19 Impact & Forecast (2021 to 2026)

Pulished: March, 2021
ID: 11386
Pages: 100

APAC Gene Therapy Market Size (2021 to 2026)

The gene therapy market in the Asia-Pacific is expected to witness the fastest growth rate among all the regions during the forecast period.

The market growth of gene therapy in APAC is mainly driven by cancer proliferation and targeted diseases, growing gene therapy techniques across the Asia Pacific. Gene therapy includes repairing, repressing, or replacing dysfunctional genes that cause disease to re-establish normal function, which is a favorable factor in market growth. Rising funding and finance activities by the governments in emerging countries such as India and China for better healthcare infrastructure and increasing research and developing activities by the researchers are further expected to drive the gene therapy market growth in this region.

Gene therapies have brought a revolutionary change in the field of health science and pharmaceuticals. The active participation of key market players has been witnessed in adapting strategies such as product development and product launch to expand their foothold in the regional market. Moreover, growing new pipeline developments for gene therapy was provided significant growth during the previous years. The factors such as acceleration of clinical trials, the introduction of new products into the market, collaborations, and product developments positively affect the market growth in Asian countries. 

Stringent regulations by the governments in Asian countries on the gene therapy market are significant restraining factors. However, lack of skilled professionals, high costs associated with the gene therapies, and unwanted immune responses impede the market growth.

Impact of COVID-19 On the APAC gene therapy market:

During the first half of 2020, the gene therapy market had been negatively impacted by the covid-19.  COVID-19 is an infectious disease that spreads quickly from person to person; governments have implemented nationwide lockdown to control the disease transmission. A ban on transportation was imposed to restrict the migrants from foreign countries. The virus was first identified in Wuhan, China, and spread across the globe. The manufacture and delivery of gene therapy treatments had been postponed as the primary focus of the government and healthcare professionals to combat the virus.

Moreover, research and clinical development, and commercial operations are the areas within the gene therapy sector that had been interrupted. The development of gene therapies has been less affected. However, the second half of 2020 was acted favorably to the market growth. Reduction in the covid-19 cases has led to the uplift of lockdown, resumed activities on gene therapies. Researchers have doubled their R&D activities, and the government is investing in regional healthcare development. It is expected that the global gene therapy market will register a healthy growth rate during the forecast period.

This research report on the Asia-Pacific Gene Therapy Market has been segmented & sub-segmented into the following categories:

 By Vector Type:

  • Viral vector
    • Retroviruses
    • Lentiviruses
    • Adenoviruses
    • Adeno-associated Virus
    • Herpes Simplex Virus
    • Poxvirus
    • Vaccinia Virus
    • Others
  • Non-viral vector
    • Naked/Plasmid Vectors
    • Gene Gun
    • Electroporation
    • Lipofection
    • Others

By Application:

  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious disease
  • Other Diseases

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, the Asia Pacific gene therapy market is estimated to be the fastest-growing region globally during the forecast period due to the factors such as an increase in the people prone to chronic diseases, a growing geriatric population, and high disposable income in this region. The major contributors in this region are China, India, and Japan.

The Chinese gene therapy market is forecasted to register the highest CAGR in the APAC market during the forecast period. Gene therapies have brought a revolutionary change in health science and pharmaceuticals in China as it replaces dysfunctional genes that cause disease to re-establish normal function. Factors such as researchers in the China region boost their activities and the high prevalence of cancer, expanding the gene therapy market.

The Indian gene therapy market is one of the fastest-growing regional markets in the APAC market. Y-O-Y rise number of people prone to chronic diseases, presence of key market players and government investments, and improving healthcare infrastructure are propelling India's market growth.

The Japanese market is projected to account for a moderate share during the forecast period in this regional market. The high prevalence rate of cancer, advancing therapies, and gene delivery technologies are expected to contribute to a better market share.

KEY MARKET PLAYERS:

Companies playing a significant role in the APAC gene therapy market profiled in this report are Biogen, Sarepta Therapeutics, Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Orchard Therapeutics Plc, Spark Therapeutics, Inc., Molmed S.P.A., Anges, Inc., Bluebird Bio, Inc., Jazz Pharmaceuticals Plc, Dynavax Technologies, Human Stem Cells Institute, Sibiono Genetech Co., Ltd., Shanghai Sunway Biotech Co., Ltd., Uniqure N.V., Gensight Biologics S.A., Celgene Corporation, Cellectis, Sangamo Therapeutics, Mustang Bio, Applied Genetic Technologies Corporation and Poseida Therapeutics, Inc.

  1. INTRODUCTION
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year, and Forecast Periods
    4. General Study Assumptions
  2. RESEARCH METHODOLOGY
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Report Overview
    1. Executive Summary
    2. Key Inferences
  4. Market Dynamics
    1. Impact Analysis
      1. Drivers
      2. Restraints
      3. Opportunities       
    2. Regulatory Environment
    3. Technology Timeline & Recent Trends
  5. Competitor Benchmarking Analysis
    1. Key Player Benchmarking                    
      1. Market share analysis      
      2. Products/Service
      3. Regional Presence               
    2. Mergers & Acquisition Landscape                     
    3. Joint Ventures & Collaborations
  6. MARKET SEGMENTATION
    1. By Vector Type
      1. Viral vector
        1. Retroviruses
        2. Lentiviruses
        3. Adenoviruses
        4. Adeno-associated Virus
        5. Herpes Simplex Virus
        6. Poxvirus
        7. Vaccinia Virus
        8. Others
      2. Non-viral vector
        1. Naked/Plasmid Vectors
        2. Gene Gun
        3. Electroporation
        4. Lipofection
        5. Others
      3. Y-o-Y Growth Analysis, By Vector Type
      4. Market Attractiveness Analysis, By Vector Type
      5. Market Share Analysis, By Vector Type
    2. By Application
      1. Oncological Disorders
      2. Rare Diseases
      3. Cardiovascular Diseases
      4. Neurological Disorders
      5. Infectious disease
      6. Other Diseases
      7. Y-o-Y Growth Analysis, By Application
      8. Market Attractiveness Analysis, By Application
      9. Market Share Analysis, By Application
  7. GEOGRAPHICAL ANALYSIS
    1. Introduction
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
      4. Market Attractiveness Analysis
      5. Market Share Analysis
    2. Asia-Pacific
      1. Introduction
      2. China
      3. India
      4. Japan
      5. South Korea
      6. Australia and NZ
      7. Rest of APAC
  8. STRATEGIC ANALYSIS
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. The threat of New Entrants
      4. The Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  9. MARKET LEADERS' ANALYSIS
    1. Biogen
      1. Overview
      2. Products
      3. Financials (subjected to availability based on company type)
      4. Recent Developments
      5. SWOT analysis
      6. Analyst View
    2. Sarepta Therapeutics
    3. Gilead Sciences, Inc.
    4. Amgen, Inc.
    5. Novartis AG
    6. Orchard Therapeutics Plc
    7. Spark Therapeutics, Inc.
    8. Molmed S.P.A.
    9. Anges, Inc.
    10. Bluebird Bio, Inc.
    11. Jazz Pharmaceuticals Plc
    12. Dynavax Technologies
    13. Human Stem Cells Institute
    14. Sibiono Genetech Co., Ltd.
    15. Shanghai Sunway Biotech Co., Ltd.
    16. Uniqure N.V.
    17. Gensight Biologics S.A.
    18. Celgene Corporation
    19. Cellectis
    20. Sangamo Therapeutics
    21. Mustang Bio
    22. Applied Genetic Technologies Corporation
    23. Poseida Therapeutics, Inc.
  10. COMPETITIVE LANDSCAPE
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  11. MARKET OUTLOOK AND INVESTMENT OPPORTUNITIES
  12. APPENDIX
  13. List of Tables
  14. List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
  • Segment-level analysis in terms of vector type and application along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies.
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
  1. Asia Pacific Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Million)
  2. Asia Pacific Viral vector Market, By Region, From 2021 to 2026 (USD Million)
  3. Asia Pacific Non-viral vector Market, By Region, From 2021 to 2026 (USD Million)
  4. Asia Pacific Gene Therapy Market, By Application, From 2021 to 2026 (USD Million)
  5. Asia Pacific Oncological Disorders Market, By Region, From 2021 to 2026 (USD Million)
  6. Asia Pacific Rare Diseases Market, By Region, From 2021 to 2026 (USD Million)
  7. Asia Pacific Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Million)
  8. Asia Pacific Neurological Disorders Market, By Region, From 2021 to 2026 (USD Million)
  9. Asia Pacific Infectious disease Market, By Region, From 2021 to 2026 (USD Million)
  10. Asia Pacific Other Diseases Market, By Region, From 2021 to 2026 (USD Million)
  11. Japan Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Million)
  12. Japan Gene Therapy Market, By Application, From 2021 to 2026 (USD Million)
  13. China Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Million)
  14. China Gene Therapy Market, By Application, From 2021 to 2026 (USD Million)
  15. India Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Million)
  16. India Gene Therapy Market, By Application, From 2021 to 2026 (USD Million)
  17. Australia Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Million)
  18. Australia Gene Therapy Market, By Application, From 2021 to 2026 (USD Million)
  19. South Korea Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Million)
  20. South Korea Gene Therapy Market, By Application, From 2021 to 2026 (USD Million)
  21. Asia Pacific Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Million)
  22. Asia Pacific Retroviruses Market, By Region, From 2021 to 2026 (USD Million)
  23. Asia Pacific Lentiviruses Market, By Region, From 2021 to 2026 (USD Million)
  24. Asia Pacific Adenoviruses Market, By Region, From 2021 to 2026 (USD Million)
  25. Asia Pacific Adeno-associated Virus Market, By Region, From 2021 to 2026 (USD Million)
  26. Asia Pacific Herpes Simplex Virus Market, By Region, From 2021 to 2026 (USD Million)
  27. Asia Pacific Poxvirus Market, By Region, From 2021 to 2026 (USD Million)
  28. Asia Pacific Vaccinia Virus Market, By Region, From 2021 to 2026 (USD Million)
  29. Japan Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Million)
  30. China Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Million)
  31. India Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Million)
  32. Australia Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Million)
  33. Asia Pacific Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Million)
  34. Asia Pacific Naked/Plasmid Vectors Market, By Region, From 2021 to 2026 (USD Million)
  35. Asia Pacific Gene Gun Market, By Region, From 2021 to 2026 (USD Million)
  36. Asia Pacific Electroporation Market, By Region, From 2021 to 2026 (USD Million)
  37. Asia Pacific Lipofection Market, By Region, From 2021 to 2026 (USD Million)
  38. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Million)
  39. Japan Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Million)
  40. China Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Million)
  41. India Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Million)
  42. Australia Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample